Publication date: Jul 15, 2025
The nucleocapsid N is one of four structural proteins of the coronaviruses. Its essential role in genome encapsidation makes it a critical therapeutic target for COVID-19 and related diseases. However, the inherent disorder of full-length N hampers its structural analysis. Here, we describe a stepwise method using viral-derived RNAs to stabilize SARS-CoV-2 N for EM analysis. We identify pieces of RNA from the SARS-CoV-2 genome that promote the formation of structurally homogeneous N dimers, intermediates of assembly, and filamentous capsid-like structures. Building on these results, we engineer a symmetric RNA to stabilize N protein dimers, the building block of high-order assemblies, for EM studies. We combine domain-specific monoclonal antibodies against N with chemical cross-linking mass spectrometry to validate the spatial arrangement of the N domains within the dimer. Additionally, our cryo-EM analysis reveals novel antigenic sites on the N protein. Our findings provide insights into N protein’s architectural and antigenic principles, which can guide design of pan-coronavirus therapeutics.

Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | role |
| disease | MESH | COVID-19 |
| disease | IDO | protein |
| pathway | REACTOME | Immune System |
| disease | MESH | infection |
| pathway | KEGG | Viral replication |
| disease | IDO | process |
| drug | DRUGBANK | Coenzyme M |